Drug intelligence / Profile preview

DMX-3001

Development stage: Preclinical
Lead developer: DemeRx

Overview

DMX-3001 is a preclinical-stage drug candidate being developed by DemeRx for the treatment of substance use disorders. It is part of the company's 'Serotonergics' program, indicating that its mechanism of action involves the modulation of the serotonin system in the central nervous system. While specific molecular targets, such as particular serotonin receptor subtypes or transporters, have not been publicly disclosed, the program aims to leverage serotonergic pathways to address addiction and related behaviors. As of early 2024, DMX-3001 remains in the early stages of development.

Other names: Serotonergics

Beyond the preview

Go deeper on DMX-3001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMX-3001.

Explore the full profile